ILMN vs. JNJ

Last updated Jun 4, 2026

ILMN (Illumina, Inc.) and JNJ (Johnson & Johnson) are both stocks. Both are in the Healthcare sector — ILMN in Diagnostics & Research, JNJ in Drug Manufacturers - General. Over the past 10 years, ILMN returned 1.90%/yr vs 9.85%/yr for JNJ. At a 0.23 correlation, their price movements are largely independent.

Performance

ILMN vs. JNJ - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Illumina, Inc. (ILMN) and Johnson & Johnson (JNJ). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, ILMN achieves a 30.32% return, which is significantly higher than JNJ's 9.07% return. Over the past 10 years, ILMN has underperformed JNJ with an annualized return of 1.90%, while JNJ has yielded a comparatively higher 9.85% annualized return.

ILMN

• 1D: 5.16%
• 1M: 22.64%
• YTD: 30.32%
• 6M: 33.59%
• 1Y: 108.88%
• 3Y*: -5.36%
• 5Y*: -15.92%
• 10Y*: 1.90%

JNJ

• 1D: 0.16%
• 1M: 0.14%
• YTD: 9.07%
• 6M: 9.93%
• 1Y: 48.18%
• 3Y*: 15.79%
• 5Y*: 9.14%
• 10Y*: 9.85%

*Multi-year figures are annualized to reflect compound growth (CAGR)

ILMN vs. JNJ - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
ILMN Illumina, Inc.	30.32%	-1.85%	-1.34%	-31.14%	-46.85%	2.82%	11.53%	10.61%	37.27%	70.64%
JNJ Johnson & Johnson	9.07%	47.48%	-4.81%	-8.58%	5.97%	11.44%	10.82%	16.22%	-5.13%	24.43%

Correlation

The correlation between ILMN and JNJ is 0.09, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.09
Correlation (3Y) Calculated over the trailing 3-year period	0.14
Correlation (5Y) Calculated over the trailing 5-year period	0.19
Correlation (10Y) Calculated over the trailing 10-year period	0.24
Correlation (All Time) Calculated using the full available price history since Jul 31, 2000	0.23

The correlation between ILMN and JNJ shifts across timeframes, from 0.09 (1 year) to 0.24 (10 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap ILMN : $26.32B JNJ : $545.87B
EPS ILMN : $5.48 JNJ : $8.65
PE Ratio ILMN : 31.21 JNJ : 25.81
PEG Ratio ILMN : 14.99 JNJ : 0.86
PS Ratio ILMN : 6.06 JNJ : 5.64
PB Ratio ILMN : 8.69 JNJ : 6.72
Total Revenue (TTM) ILMN : $4.39B JNJ : $96.36B
Gross Profit (TTM) ILMN : $2.93B JNJ : $66.60B
EBITDA (TTM) ILMN : $1.39B JNJ : $31.62B

Return for Risk

ILMN vs. JNJ — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ILMN

ILMN Risk / Return Rank: 88
ILMN Sharpe Ratio Rank: 90
ILMN Sortino Ratio Rank: 90
ILMN Omega Ratio Rank: 87
ILMN Calmar Ratio Rank: 88
ILMN Martin Ratio Rank: 86

JNJ

JNJ Risk / Return Rank: 92
JNJ Sharpe Ratio Rank: 94
JNJ Sortino Ratio Rank: 95
JNJ Omega Ratio Rank: 93
JNJ Calmar Ratio Rank: 89
JNJ Martin Ratio Rank: 91

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ILMN vs. JNJ - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Illumina, Inc. (ILMN) and Johnson & Johnson (JNJ). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ILMN	JNJ	Difference
Sharpe ratio Return per unit of total volatility	2.33	2.91	-0.57
Sortino ratio Return per unit of downside risk	3.26	4.26	-1.00
Omega ratio Gain probability vs. loss probability	1.39	1.52	-0.13
Calmar ratio Return relative to maximum drawdown	4.27	4.42	-0.15
Martin ratio Return relative to average drawdown	9.67	13.33	-3.65
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ILMN vs. JNJ - Sharpe Ratio Comparison

The current ILMN Sharpe Ratio is 2.33, which is comparable to the JNJ Sharpe Ratio of 2.91. The chart below compares the historical Sharpe Ratios of ILMN and JNJ, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	ILMN	JNJ	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.33	2.91	-0.57
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.35	0.55	-0.90
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.05	0.54	-0.49
Sharpe Ratio (All Time) Calculated using the full available price history	0.16	0.53	-0.38

Drawdowns

ILMN vs. JNJ - Drawdown Comparison

The maximum ILMN drawdown since its inception was -96.14%, which is greater than JNJ's maximum drawdown of -50.67%. Use the drawdown chart below to compare losses from any high point for ILMN and JNJ.

Drawdown Indicators

	ILMN	JNJ	Difference
Max Drawdown Largest peak-to-trough decline	-96.14%	-50.67%	-45.47%
Max Drawdown (1Y) Largest decline over 1 year	-25.66%	-10.96%	-14.70%
Max Drawdown (3Y) Largest decline over 3 years	-65.68%	-15.95%	-49.73%
Max Drawdown (5Y) Largest decline over 5 years	-86.23%	-18.41%	-67.82%
Max Drawdown (10Y) Largest decline over 10 years	-86.23%	-27.37%	-58.86%
Current Drawdown Current decline from peak	-66.52%	-9.67%	-56.85%
Average Drawdown Average peak-to-trough decline	-40.37%	-11.88%	-28.49%
Ulcer Index Depth and duration of drawdowns from previous peaks	11.30%	3.63%	+7.67%

Volatility

ILMN vs. JNJ - Volatility Comparison

Illumina, Inc. (ILMN) has a higher volatility of 9.58% compared to Johnson & Johnson (JNJ) at 5.20%. This indicates that ILMN's price experiences larger fluctuations and is considered to be riskier than JNJ based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ILMN	JNJ	Difference
Volatility (1M) Calculated over the trailing 1-month period	9.58%	5.20%	+4.38%
Volatility (6M) Calculated over the trailing 6-month period	29.23%	12.17%	+17.06%
Volatility (1Y) Calculated over the trailing 1-year period	46.92%	16.67%	+30.25%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	45.66%	16.82%	+28.84%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	42.17%	18.45%	+23.72%

Dividends

ILMN vs. JNJ - Dividend Comparison

ILMN has not paid dividends to shareholders, while JNJ's dividend yield for the trailing twelve months is around 2.35%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
ILMN Illumina, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
JNJ Johnson & Johnson	2.35%	2.48%	3.40%	3.00%	2.52%	2.45%	2.53%	2.57%	2.74%	2.38%	2.73%	2.87%

Financials

ILMN vs. JNJ - Profitability Comparison

The chart below illustrates the profitability comparison between Illumina, Inc. and Johnson & Johnson over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

ILMN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Illumina, Inc. reported a gross profit of 721.00M and revenue of 1.09B. Therefore, the gross margin over that period was 66.1%.

JNJ - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Johnson & Johnson reported a gross profit of 17.20B and revenue of 24.06B. Therefore, the gross margin over that period was 71.5%.

ILMN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Illumina, Inc. reported an operating income of 209.00M and revenue of 1.09B, resulting in an operating margin of 19.2%.

JNJ - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Johnson & Johnson reported an operating income of 6.40B and revenue of 24.06B, resulting in an operating margin of 26.6%.

ILMN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Illumina, Inc. reported a net income of 134.00M and revenue of 1.09B, resulting in a net margin of 12.3%.

JNJ - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Johnson & Johnson reported a net income of 5.24B and revenue of 24.06B, resulting in a net margin of 21.8%.

Frequently Asked Questions

Can I hold both ILMN and JNJ in my portfolio?

ILMN and JNJ have a correlation of 0.09, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, ILMN or JNJ?

ILMN has higher volatility (9.58%) compared to JNJ (5.20%). In terms of maximum drawdown, ILMN dropped -96.14% vs JNJ's -50.67%.

Which has better risk-adjusted returns?

JNJ currently has the higher Sharpe Ratio (2.91 vs 2.33), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.